Article Sidebar
Published:
May 23, 2005Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparative <i>in-vitro</i> studies on the efficacy of ivermectin against gastrointestinal sheep nematode
Abstract
Method: Ivermectin injections were evaluated by a larval development assay (LDVA), using the larvae of Strongyles (predominantly Haemonchus contortus) of sheep. The effect of standard solutions of the drug from the various brands on the transformation of L1 to L3 and survival of L3 larvae was used to assess bioactivity. The 50% lethal concentration (LC50) was determined from regression line obtained by probit transformation of the biological data. The LC50 values for each of the brands were compared with that of the innovator brand (Ivomec Superâ) for any significant difference.
Results: The LC50 values obtained for the five brands varied widely. It ranges from 1.1±0.17 ng/ml for the innovator brand to 2.3±0.3, 3.0±0.3, 8.0±0.2 and 17.0±0.3 ng/ml for the other four brands. The biological assays performed on each of the five brands were of comparable precision. LC50 for Ivomec superâ was significantly different from those of the other four brands (Student's t test, p < 0.01).
Conclusion: The bioactivities of brands of ivermectin injections available in Nigeria are significantly different. This is a probable reason for the varied treatment response to various brands of ivermectin injection in veterinary practice in Nigeria. This justifies the need for drug regulatory bodies in Nigeria to ensure that ivermectin injections registered for use in Nigeria meets approved standards before the drugs are allowed to be imported into the country.
Key words: Bioactivity, ivermectin, sheep nematode
Trop J Pharm Res, December 2003; 2(2): 235-239
